-
DOSIsoft Announces New FDA 510(k) Clearance for PLANET® Onco Dose
- March 25, 2025
DOSIsoft, SA is proud to announce its latest product release, PLANET® Onco Dose version 3.2 received FDA 510(k) Clearance on March 14, 2025 from the US Food and Drug Administration, following its EU MDR CE Mark certification. The novel PLANET® platform is designed to incorporate a multi-radionuclide approach, implement multi-workflow solutions, and support multi-therapy applications for both SIRT (Selective Internal Radiation Therapy) and MRT (Molecular Radiation Therapy) while ensuring compliance with U.S. standards.
-
PLANET® Onco Dose Receives EU MDR CE Mark certification
- March 4, 2025
DOSIsoft is proud to announce that its latest product release, PLANET® Onco Dose version 3.2 – multi-radionuclide, personalized, voxel-based dosimetry platform for both SIRT and MRT – received Medical Device Regulation (MDR) CE Mark on February 17, 2025, under the new (EU) Regulation 2017/745.
-
DOSIsoft Contributing Partner of the European Thera4Care project – Theranostics Ecosystem For Personalized Care
- October 11, 2024
DOSIsoft is proud to be part of the EU-funded Thera4care Project – a public-private initiative aiming to revolutionize precision oncology and establish Europe as a global leader in Theranostics. Contributing with its own R&D and granted 1,6 million€ of EU funding, DOSIsoft will focus its efforts on the further development of dosimetry software, sharing the vision that personalized dosimetry becomes a standard clinical practice.
-
DOSIsoft & AP-HP: A Scientific partnership on « QUANTHYR » – 1st Software dedicated to Personalized Diagnosis and Dosimetry Treatment of Hyperthyroidism with 131Iodine
- October 1, 2024
RESEARCH & INNOVATION IN NUCLEAR MEDICINE: To improve cancer patient safety and treatment quality, DOSIsoft announces that it has signed a development and commercialization agreement (license) with the Assistance Publique – Hôpitaux de Paris (AP-HP) for a Radioiodine theranostic solution applied to benign thyroid diseases named “QUANTHYR”.
-
TuxCare and DOSIsoft Partner to Offer Ongoing Support and Cyber Protections for Radiation Oncology and Nuclear Medicine Software
- May 21, 2024
TuxCare and DOSIsoft Partner to offer ongoing support and cyber protections for Radiation Oncology and Nuclear Medicine Software. Hospitals worldwide to be offered extended lifecycle support and security alongside five DOSIsoft solutions.
-
ThinkQA Secondary Dose Check is FDA 510(k) Cleared for Conventional and online Adaptive RadioTherapy
- February 12, 2024
DOSIsoft is pleased to share that it has obtained 510(k) clearance from the US Food and Drug Administration (FDA) on January 18th, 2024, for the commercialization of ThinkQA (Edition 2) Secondary Dose Check. This advanced Patient Quality Assurance (QA) for External Beam Radiation Therapy (EBRT) tool offers reliable, automated, and 3D independent calculation-based dose verification, specifically crafted for both offline and online adaptive workflows.
-
DOSIsoft launches new ThinkQA Secondary Dose Check solution designed for Adaptive Radiotherapy Workflows
- May 9, 2023
DOSIsoft is proud to announce its latest innovation – ThinkQA Secondary Dose Check – a fast, reliable, and independent 3D dose calculation for online adaptive workflows. CE marked on April 14th, 2023, the new software product will succeed the current MU2net solution and offers a technology breakthrough and cost-effective solution for Secondary dose calculation and verification. It will be of great value for Radiation Therapy (RT) departments to perform routine Patient-specific Quality Assurance (QA) and meet the QA requirements of the latest adaptive radiotherapy equipment and practices.
-
2002-2022: DOSIsoft Delivering 20 Years of Innovation
- May 5, 2022
2022 is a milestone year for DOSIsoft – Leading provider of Patient-specific software solutions for Radiation Oncology and Nuclear Medicine – celebrating its 20-year-involvement in delivering innovation for cancer care worldwide.
-
DOSIsoft welcomes John SEDDO, New Global Customer Services Director
- July 23, 2021
To support its global strong growth especially in the field of Radiation Oncology & Quality Assurance, DOSIsoft announces the nomination of Mr. John SEDDO, as new Director of Customer Support Services Worldwide. Based in US, he will manage globally the DOSIsoft Customer Services activities.
-
DOSIsoft MU2net is FDA 510(k) Cleared for Patient QA – Secondary Dose Calculation
- November 7, 2019
DOSIsoft, leading provider of patient-specific software solutions for Radiation Oncology and Nuclear Medicine, is pleased to announce that on October 24th, 2019, it received 510(k) clearance from the US Food and Drug Administration (FDA), to market MU2net, software dedicated to Independent Secondary Dose Calculation for Patient Quality Assurance (QA).
